Corporate Banner
Satellite Banner
Stem Cells, Cellular Therapy & Biobanking
>
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Cancer Immunotherapy Can Use Small Numbers of Stem-Like Immune Cells to Destroy Large Tumors in Mice

Published: Friday, June 26, 2009
Last Updated: Friday, June 26, 2009
Bookmark and Share
New approach to stimulating immune cells enhances their anticancer activity, resulting in a powerful anti-tumor response in mice.

A new approach to stimulating immune cells enhances their anticancer activity, resulting in a powerful anti-tumor response in mice, according to a study by researchers at the National Cancer Institute, a part of the National Institutes of Health. This work represents an important advance in the development of immunotherapy for cancer and appears online June 14, 2009 in Nature Medicine.

Researchers found that a subset of immune cells, T lymphocytes called CD8+ memory stem cells, were capable of mediating strong anti-tumor immune response. These potent cells were generated in the laboratory by stimulating anti-tumor T cells in the presence of drugs designed to mimic an important signaling pathway called Wnt, which describes a complex network of proteins whose interactions are essential during development and stem cell maintenance.

Under the influence of Wnt, T lymphocytes acquired stem cell-like properties of multipotency and self renewal; that is, they generated differentiating daughter cells while regenerating themselves when transferred back to mice from the lab. These stem cell-like qualities enabled tiny numbers of T cells to trigger the destruction of large melanoma tumors.

This therapy, in which mice received CD8+ T memory stem cells together with a tumor vaccine and an immune system stimulant known as interleukin 2, improved the survival of treated mice compared with similar treatment using other types of memory T cells.

"This new category of lymphocytes is superior to T cells used in earlier experiments because they have the enhanced ability to renew themselves, to proliferate, to differentiate and ultimately to kill tumor cells," said NCI lead author Nicholas P. Restifo, M.D., an investigator in the Surgery Branch at the Center for Cancer Research.

Current clinical immunotherapies based on the transfer of tumor-specific T cells generated and expanded in the laboratory rely on the use of large numbers of tumor-specific T cells and have had beneficial but sometimes limited success.

If confirmed in humans, the use of tumor-reactive CD8+ memory stem cells could reduce the numbers of tumor-specific T cells needed for successful immunotherapy, thus making this type of therapy easier to develop so that more patients could benefit.

These findings mark the latest advance in the field of cancer immunotherapy using tumor-specific T cells, which is moving from proof-of-concept to a promising treatment for patients with metastatic cancer.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 4,000+ scientific posters on ePosters
  • More than 5,300+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Stem Cell Transplant Without Radiation or Chemotherapy
Researchers have successfully performed stem cell transplants without using radiation or chemotherapy.
Friday, September 09, 2016
NCI Embraces Recommendations for Cancer Moonshot
NCI accepts recommendations for approaches likely to make progress against cancer under the Cancer Moonshot
Thursday, September 08, 2016
Engineered Stem Cells Identify Medulloblastoma Treatment
Researchers have engineered neural stem cells to carry mutations thought to drive a particular subtype of medulloblastoma.
Monday, September 05, 2016
2011 Biospecimen Research Network (BRN) Symposium
The National Cancer Institute's (NCI) Biospecimen Research Network Symposium, "Advancing Cancer Research Through Biospecimen Science," will be held March 28-29, 2011, at the Bethesda North Marriott Hotel & Conference Center in Bethesda, MD
Friday, January 07, 2011
Scientists Identify Markers on Human Breast Cancer Cells Linked to Development of a Form of Breast Cancer
The scientists named these human cells with tumor-forming ability in mice, xenograft-initiating cells, or XIC.
Friday, May 21, 2010
Drug for Multiple Myeloma Demonstrated to Extend Disease-Free Survival
Patients receiving lenalidomide following a blood stem cell transplant had their cancer kept in check longer than placebo receiving patients.
Thursday, December 24, 2009
Mouse Studies Show Gene Therapy Method Holds Promise in Targeting Tumor Blood Vessels for Destruction
Cancer researchers develop method for delivering a therapeutic gene specifically to the blood vessels of tumors in mice.
Thursday, December 18, 2008
Researchers Develop a Method to Evaluate Variations Identified in Breast Cancer Susceptibility Genes
The researchers believe that the new test could become a useful and viable tool for genetic counselors, and may have implications beyond cancer.
Tuesday, July 08, 2008
Method of Gene Therapy Alters Immune Cells for Treatment of Advanced Melanoma
Technique may also apply to other common cancers.
Friday, September 01, 2006
Scientific News
Stem Cells in Drug Discovery
Potential Source of Unlimited Human Test Cells, but Roadblocks Remain.
Genetics Control Regenerative Properties Of Stem Cells
Researchers define how genetic factors control regenerative properties of blood-forming stem cells.
Allen Institute Releases Gene Edited Human Stem Cell Lines
The Allen Cell Collection, a publicly available collection of gene edited pluripotent stem cells, has been made available by the Allen Institute.
Designer Cell Fate Switches Could Streamline Stem Cell Biology
Researchers develop new method of reprogramming cells between cell types in a more efficient way than before.
Improving Drug Production with Computer Model
A model has been developed that can be used to improve and accelerate the production of biotherapeutics, cancer drugs, and vaccines.
Defining the Immortality of Stem Cells
Researchers defined the mechanisms underlying increased protein quality control of pluripotent stem cells.
BioCision Forms MedCision
The new company will focus on technologies for the management and automation of vital clinical processes.
Enhancing CRISPR to Explore Further
Researchers have developed sOPTiKO, a more efficient and controllable CRISPR genome editing platform.
Stem Cells Police Themselves to Reduce Scarring
Scientists have discovered stem cells in muscle fibers change gene expressions to respond to injury.
Regenerating Diseased Hearts
Researchers from the University of Otago have probed the potential of adult stem cell types to repair diseased hearts.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
4,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,300+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!